Infection à VIH : une rémission possible Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France
Viral reservoirs persist in HIV-infected individuals receiving cart T cell differentiation Naive Central Memory Transitional Memory Effector Memory Finzi et al. Cells 1997 Half-life cart duration to eliminate
Viral replication resumes as soon as therapy is interrupted
Targeting viral reservoirs Draining Eradication Limiting Remission
HIV controllers (HIC): infected individuals spontaneously controlling HIV-1 infection Cell restriction Innate responses(nk/pdc) Reduced dynamics of viral replication Attenuated virus Preserved immune functions Repression of viral reservoir Plasma Viral loa ad CTL Progressor Optimal T response Time HIC Pancino and Saez-Cirion. Immunological Reviews. 213
Favorable genetic background and Efficient CD8 T cell responses are associated with control 1 8 B27 B57 B14 1 4 CD4 T cells CD4:CD8 1:1 1 3 % of patie ents 6 4 2 p24 (ng/ml) 1 2 1 1 1 1-1 3 7 1 Days post infection France Primo ANRS CO6 HIC ANRS CO18 Saez-Cirion et al, PNAS 27; Nature Protocols 21 Greater and faster upregultaion of cytotoxic mediators Migueles, et al. Immunity 28; Hersperger, et al. PLoS Pathogens 21 High functional avidity Almeida, et al. JEM 27 MHC and TCR plasticity Chen et al Nat Immunol212; Pereyraet al Science 21; Bailey et al JEM 26
Is it possible to induce a HIV controller-like status? VISCONTI Study Virological and Immunological Studies in CONtrollers after Treatment Interruption
ANRS VISCONTI: Post-TreatmentControllers(PTC) OR1 1 9 2 1 8 1 7 15 1 6 1 5 1 1 4 1 3 5 1 2 1 1 96 98 2 4 6 8 1 1 OR2 1 9 2 1 8 1 15 7 1 6 1 1 5 1 4 5 1 3 1 2 1 1 1 2 3 4 5 6 7 8 9 1 11 KPV 1 9 2 1 8 1 7 15 1 6 1 5 1 1 4 1 3 5 1 2 1 1 1 1 2 3 4 5 6 7 8 9 1 11 OR8 1 9 2 1 8 1 7 15 1 6 1 5 1 1 4 1 3 5 1 2 1 1 1 98 99 1 2 3 4 5 6 7 8 9 1 11 1 9 2 1 8 1 7 15 1 6 1 5 1 1 4 1 3 5 1 2 1 1 1 99 1 2 3 4 5 6 7 8 9 2 15 1 5 99 1 2 3 4 5 6 7 8 9 1 1 9 1 8 1 7 1 6 1 5 1 4 1 3 1 2 1 1 1 2 15 1 5 2 15 1 5 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 OR3 GXR JOGA LY2 1 9 2 1 8 1 15 7 1 6 1 1 5 1 4 5 1 3 1 2 11 96 98 2 4 6 8 1 12 MO1 1 9 2 1 8 1 7 15 1 6 1 5 1 1 4 1 3 5 1 2 1 1 1 99 1 2 3 4 5 6 7 8 9 1 11 12 1 9 2 1 8 1 7 15 1 6 1 5 1 1 4 1 3 5 1 2 1 1 1 98 99 1 2 3 4 5 6 7 8 9 1 SL2 1 9 2 1 8 1 7 15 1 6 1 5 1 1 4 1 3 5 1 2 1 1 1 99 1 2 3 4 5 6 7 8 9 1 11 12 2 15 1 5 CXK MWP 2 3 4 5 6 7 8 9 1 1 9 1 8 1 7 1 6 1 5 1 4 1 3 1 2 1 1 1 2 15 1 5 OCP LY1 1 2 3 4 5 6 7 8 9 1 11 1 9 1 8 1 7 1 6 1 5 1 4 1 3 1 2 1 1 1 1 9 1 8 1 7 1 6 1 5 1 4 1 3 1 2 1 1 1 1 9 1 8 1 7 1 6 1 5 1 4 1 3 1 2 1 1 1 Therapy started within 1 weeks following Primary Infection Therapy started 39 days p.i. 3 years on therapy followed by 7.5 years of control off therapy Saez-Cirion et al PLoS Path 213
Post-treatment controllers have a tougher primary infection than HIV controllers CD4+ T cellscountsatphi (cells/µl) 12 1 8 6 4 2 p=.2 p=.88 pre-hic pre-ptc PRIMO Non controllers Plasma RNA Viral loadatphi (log copies/ml) 8 6 4 2 p=.2 p=.68 pre-hic pre-ptc PRIMO Non controllers Saez-Cirion et al PLoS Path 213
Post-treatment controllers don t have a favorable MHC background Allele freq quency (%) 6 5 4 3 2 1 B27 B57 B35 B7 France HIC PTC Saez-Cirion et al PLoS Path 213
Post-treatment controllers have weak HIV-specific CD8+ T cell responses IFNγ(SFC/1 1 6 PBMC) 12 1 8 6 4 2 IFNγ ELISPOT <.1 <.1 <.1 <.1 VIR HAART HIC PTC log p24 decrease (CD D4 vs CD4:CD8) 4 3 2 1 HIV suppression <.1 <.1 <.1 VIR HAART HIC PTC Saez-Cirion et al PLoS Path 213
Post-treatment controllers have weak levels of T cell activation 7 6 5 p <.1 HAART HIC PTC % of CD3+ CD8+ cells 4 3 2 1 p <.1 CD38+ HLA-DR+ CD38+HLA-DR+ Saez-Cirion et al PLoS Path 213
Post-treatment controllers have low levels of HIV-1 DNA in PBMC, which further decreased after treatment interruption in some cases 6 4 HIV-DNA (log1 copies/1 6 PBMC) 5 4 3 2 1 PHI Chronic cart ALT HIC PTC Cell associa ated HIV-1 DNA (Log copie es/16 PBMC) 3 2 1 3 6 9 12 Time after treatment interruption (months) Saez-Cirion et al PLoS Path 213
Skewed CD4 subsets distribution in PTC impacts the subsets contribution to the HIV reservoir Resting CD4 Cell Subsets Contribution to the HIV reservoir Infection level* blood frequency of subset T cell differentiation Subset cont tribution to the resting HIV reservoir(%) 1 8 6 4 2 * ** ** ** ** T N T C M T T M T E M PTC T N T C M T T M T E M HICI Naive Central Memory Transitional Effector Memory Memory Cellhalf-life A contribution to the HIV reservoir: - Major for TTM subset - Lowfor the TN and TCM subsets Saez-Cirion et al PLoS Path 213
A long-termtreatmentinitiatedduringprimaryinfection seems to increase the chances to control viremia Natural control of infection: 81 HIC from 34 317 patients followed-up:.24% Buffassa et al, PLoS One 211 Early treatment induced control of infection: Hocqueloux et al AIDS 21: N=32 patients, 15.6% VL<5 at M24 Goujardet al AntivirTher213: N=164 patients, 8.5%VL<5 atm24 3538 patients included in the FHDH within 6 months of primary infection 1997-211 756patients treated within 6 months and at least for a year 74patients with a viral load below <5 who stop Probability to loss control Probability to keep controlling infection at24m (lossof control: 2VL>5 or 1VL>5 +cart) : 15.7%[6.5-28.5] Months post-treatment interruption Saez-Cirion et al PLoS Path 213
HIC vs PTC HIV controllers (HIC) Asymptomatic primary infection, low viral loadsandhighcd4tcellcountsinphi 8% HIC carry one protective HLA-class I allele Generally strong HIV-specific T cell responses with strong capacity to eliminate infected cells Abnormal high levels of T cell activation Post-Treatment Controllers (PTC) Symptomatic primary infection, high viral loadsandlowcd4tcellcountsinphi 57% PTC carry one HLA-class I allele associated with high viral loads Generally very weak HIV-specific T cell responses with poor capacity to eliminate infected cells Low levels of T cell activation Estimated frequency: infected patients.5% of HIV Estimated frequency: 5-15% of HIV infected patients interrupting a >12 months-length treatment initiated in primary infection
Conclusions from the VISCONTI study We have identified a group of HIV patients in virological remission, who are able to maintain a durable control of viral replication after treatment interruption. Overall, these patients have a different HLA profile, lower frequency and quality of HIVspecific CD8+ T cell responses, and lower CD8+ T cell activation than natural HIV controllers. Post-treatment controllers have a weak HIV reservoir in which there is a minor contribution of long-lived cells. Post-treatment control Patients in the VISCONTI study was likely achieved through early and long-lasting therapeutic intervention.
cart initiation during primary infection deeply impacts on HIV reservoirs HIV-1 DNA (Log / M PBMC) PHI CHI Time with undetectable viral load (years) Hocqueloux et al, JAC 213
However, a weak HIV reservoir is not enough
EARLY TREATMENT Limiting the establishment of the viral reservoir Limiting viral diversity Reducing immune activation Preserving and cooperating with immune responses Limiting the dynamics of viral replication in acute infection may be crucial for spontaneous control of infection
HIV remission in a 28-month old Perinatally-infected child (Mississippi Toddler) Persaud et al, CROI 213
World-wide observations of post-treatment controllers 2 PTC Remember: treatment interruption is not recommended outside structured protocols!!!
The ANRS International VISCONTI Post Treatment Controller Cohort OBJECTIVES To build an international cohort of Post Treatment Controllers in order to : Uncover mechanisms underlying viral control, i.e. HIV remission Identify predictive markers associated with viral control after treatment interruption Main Outcome: To identify patients in whom HAART could be safely interrupted CONTACT : visconti@anrs.fr
Acknowledgements Patients and clinicians who participate in the studies ANRS CO6 PRIMO ANRS CO18 HIV controllers ANRS CO15 ALT Institut Pasteur Régulation des Infections Rétrovirales Gianfranco Pancino Françoise Barré-Sinoussi Chiraz Hamimi Annie David Pierre Versmisse Awatef Allouch Anna Bergamaschi Daniel Scott-Algara FHDH French Hospital Database on HIV CHU Necker Laboratoire de Virologie Christine Rouzioux Véronique Avettand-Fenoel Adeline Mélard CHR Orléans La Source Service Maladies Infectieuses Laurent Hocqueloux Thierry Prazuck Kremlin-Bicetre INSERM U112 Alain Venet Olivier Lambotte Cécile Goujard Jean-François Delfraissy Isabelle Girault Camille Lecuroux INSERM U118 Laurence Meyer Faroudy Boufassa George Nembot CHU Pitié-Salpetriere INSERM UMR-S 945 Brigitte Autran Victor Appay Charline Bacchus Benjamin Descours Assia Samri Ioannis Theodorou Julien Guergnon INSERM UPMC U943 Dominique Costagliola Valérie Portard